{"id":"metronidazole","rwe":[{"pmid":"41905430","year":"2026","title":"The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions.","finding":"","journal":"Gastroenterology","studyType":"Clinical Study"},{"pmid":"41904345","year":"2026","title":"UV-spectrometric study of antibiotic long-term release by different osteoplastic materials used in dentistry.","finding":"","journal":"The Saudi dental journal","studyType":"Clinical Study"},{"pmid":"41903526","year":"2026","title":"Vaginal microbiota impacts of a Lactobacillus crispatus live biotherapeutic and predictors of colonization in randomized controlled trial.","finding":"","journal":"Cell host & microbe","studyType":"Clinical Study"},{"pmid":"41902724","year":"2026","title":"Multifloraflavone and polyphenols from Garcinia multiflora with antioxidant, anti-acetylcholinesterase, and anti-Helicobacter pylori activities.","finding":"","journal":"Natural product research","studyType":"Clinical Study"},{"pmid":"41902546","year":"2026","title":"The use of design of experiments and green chemistry for the preparation of a taste-masked metronidazole-loaded cubosomal nanostructured oral gel.","finding":"","journal":"Pharmaceutical development and technology","studyType":"Clinical Study"}],"_fda":{"id":"29651ae0-6297-4821-9b15-9d7753e1a3b8","set_id":"02046a22-a5eb-4bb7-bec7-e5a2aa55e142","openfda":{"nui":["N0000175435","M0014907"],"unii":["140QMO216E"],"route":["ORAL"],"rxcui":["314106"],"spl_id":["29651ae0-6297-4821-9b15-9d7753e1a3b8"],"brand_name":["Metronidazole"],"spl_set_id":["02046a22-a5eb-4bb7-bec7-e5a2aa55e142"],"package_ndc":["50090-0201-1","50090-0201-0","50090-0201-2"],"product_ndc":["50090-0201"],"generic_name":["METRONIDAZOLE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_cs":["Nitroimidazoles [CS]"],"substance_name":["METRONIDAZOLE"],"pharm_class_epc":["Nitroimidazole Antimicrobial [EPC]"],"manufacturer_name":["A-S Medication Solutions"],"application_number":["ANDA203458"],"original_packager_product_ndc":["29300-226"]},"version":"23","warnings":["WARNINGS Hypersensitivity Reactions Hypersensitivity reactions including severe cutaneous adverse reactions (SCARs) can be serious and potentially life threatening (see ADVERSE REACTIONS ). Severe Cutaneous Adverse Reactions Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), and acute generalized exanthematous pustulosis (AGEP) have been reported with the use of metronidazole. Symptoms can be serious and potentially life threatening (If symptoms or signs of SCARs develop, discontinue metronidazole tablets immediately and institute appropriate therapy. Central and Peripheral Nervous System Effects Encephalopathy and peripheral neuropathy: Cases of encephalopathy and peripheral neuropathy (including optic neuropathy) have been reported with metronidazole. Encephalopathy has been reported in association with cerebellar toxicity characterized by ataxia, dizziness, and dysarthria. CNS lesions seen on MRI have been described in reports of encephalopathy. CNS symptoms are generally reversible within days to weeks upon discontinuation of metronidazole. CNS lesions seen on MRI have also been described as reversible. Peripheral neuropathy, mainly of sensory type has been reported and is characterized by numbness or paresthesia of an extremity. Convulsive seizures have been reported in patients treated with metronidazole. Aseptic meningitis: Cases of aseptic meningitis have been reported with metronidazole. Symptoms can occur within hours of dose administration and generally resolve after metronidazole therapy is discontinued. The appearance of abnormal neurologic signs and symptoms demands the prompt evaluation of the benefit/risk ratio of the continuation of therapy (see ADVERSE REACTIONS )."],"pregnancy":["Pregnancy: Teratogenic Effects There are no adequate and well controlled studies of metronidazole in pregnant women. There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5000 pregnant women who used metronidazole during pregnancy. Many studies included first trimester exposures. One study showed an increased risk of cleft lip, with or without cleft palate, in infants exposed to metronidazole in-utero; however, these findings were not confirmed. In addition, more than ten randomized placebo-controlled clinical trials enrolled more than 5000 pregnant women to assess the use of antibiotic treatment (including metronidazole) for bacterial vaginosis on the incidence of preterm delivery. Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy. Three studies conducted to assess the risk of infant cancer following metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited. Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known. Reproduction studies have been performed in rats, rabbits, and mice at doses similar to the maximum recommended human dose based on body surface area comparisons. There was no evidence of harm to the fetus due to metronidazole."],"overdosage":["OVERDOSAGE Single oral doses of metronidazole, up to 15 g, have been reported in suicide attempts and accidental overdoses. Symptoms reported include nausea, vomiting, and ataxia. Oral metronidazole has been studied as a radiation sensitizer in the treatment of malignant tumors. Neurotoxic effects, including seizures and peripheral neuropathy, have been reported after 5 to 7 days of doses of 6 to 10.4 g every other day. Treatment of Overdosage: There is no specific antidote for metronidazole overdose; therefore, management of the patient should consist of symptomatic and supportive therapy."],"description":["DESCRIPTION Metronidazole tablets, USP 250 mg or 500 mg is an oral formulation of the synthetic nitroimidazole antimicrobial, 2-methyl-5-nitro-1H-imidazole-1-ethanol, which has the following structural formula: Metronidazole tablets USP contain 250 mg or 500 mg of metronidazole. Inactive ingredients include powdered cellulose, hydroxypropyl cellulose, low substituted hydroxypropyl cellulose, hypromellose, polyethylene glycol, stearic acid, and titanium dioxide. Molecular Structure"],"precautions":["PRECAUTIONS General Hepatic Impairment Patients with hepatic impairment metabolize metronidazole slowly, with resultant accumulation of metronidazole in the plasma. For patients with severe hepatic impairment (Child-Pugh C), a reduced dose of metronidazole is recommended. For patients with mild to moderate hepatic impairment, no dosage adjustment is needed but these patients should be monitored for metronidazole associated adverse events (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION ). Renal Impairment Patients with end-stage renal disease may excrete metronidazole and metabolites slowly in the urine, resulting in significant accumulation of metronidazole metabolites. Monitoring for metronidazole associated adverse events is recommended (see CLINICAL PHARMACOLOGY ). Fungal Superinfections Known or previously unrecognized candidiasis may present more prominent symptoms during therapy with metronidazole and requires treatment with a candidacidal agent. Use in Patients with Blood Dyscrasias Metronidazole is a nitroimidazole and should be used with caution in patients with evidence of or history of blood dyscrasia. A mild leukopenia has been observed during its administration; however, no persistent hematologic abnormalities attributable to metronidazole have been observed in clinical studies. Total and differential leukocyte counts are recommended before and after therapy. Drug-Resistant Bacteria and Parasites Prescribing metronidazole in the absence of a proven or strongly suspected bacterial or parasitic infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria and parasites. Information for Patients Interaction with Alcohol Discontinue consumption of alcoholic beverages or products containing propylene glycol while taking metronidazole and for at least three days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur (see CONTRAINDICATIONS and PRECAUTIONS, Drug Interactions ). Treatment of Bacterial and Parasitic Infections Patients should be counseled that metronidazole should only be used to treat bacterial and parasitic infections. Metronidazole does not treat viral infections ( e.g., the common cold). When metronidazole is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by metronidazole in the future. Severe Cutaneous Adverse Reactions Advise patients that metronidazole tablets may increase the risk of serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), and drug reaction with eosinophilia and systemic symptoms (DRESS). Instruct the patient to be alert for skin rash, blisters, fever or other signs and symptoms of these hypersensitivity reactions. Advise patients to stop metronidazole tablets immediately if they develop any type of rash and seek medical attention. Drug Interactions Disulfiram Psychotic reactions have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Metronidazole should not be given to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS ). Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy (see CONTRAINDICATIONS ). Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. When metronidazole is prescribed for patients on this type of anticoagulant therapy, prothrombin time and INR should be carefully monitored. Lithium In patients stabilized on relatively high doses of lithium, short-term metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning metronidazole to detect any increase that may precede clinical symptoms of lithium intoxication. Busulfan Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Metronidazole should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to metronidazole are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly. Drugs that Inhibit CYP450 Enzymes The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of metronidazole. Drugs that Induce CYP450 Enzymes The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported. Drugs that Prolong the QT interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. Drug/Laboratory Test Interactions Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD+ NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7 . Carcinogenesis, Mutagenesis, Impairment of Fertility Tumors affecting the liver, lungs, mammary, and lymphatic tissues have been detected in several studies of metronidazole in rats and mice, but not hamsters. Pulmonary tumors have been observed in all six reported studies in the mouse, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). Malignant liver tumors were increased in male mice treated at approximately 1500 mg/m 2 (similar to the maximum recommended daily dose, based on body surface area comparisons). Malignant lymphomas and pulmonary neoplasms were also increased with lifetime feeding of the drug to mice. Mammary and hepatic tumors were increased among female rats administered oral metronidazole compared to concurrent controls. Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative. Metronidazole has shown mutagenic activity in in vitro assay systems including the Ames test. Studies in mammals in vivo have failed to demonstrate a potential for genetic damage. Metronidazole failed to produce any adverse effects on fertility or testicular function in male rats at doses up at 400 mg/kg/day (similar to the maximum recommended clinical dose, based on body surface area comparisons) for 28 days. However, rats treated at the same dose for 6 weeks or longer were infertile and showed severe degeneration of the seminiferous epithelium in the testes as well as marked decreases in testicular spermatid counts and epididymal sperm counts. Fertility was restored in most rats after an eight week, drug-free recovery period. Pregnancy: Teratogenic Effects There are no adequate and well controlled studies of metronidazole in pregnant women. There are published data from case-control studies, cohort studies, and 2 meta-analyses that include more than 5000 pregnant women who used metronidazole during pregnancy. Many studies included first trimester exposures. One study showed an increased risk of cleft lip, with or without cleft palate, in infants exposed to metronidazole in-utero; however, these findings were not confirmed. In addition, more than ten randomized placebo-controlled clinical trials enrolled more than 5000 pregnant women to assess the use of antibiotic treatment (including metronidazole) for bacterial vaginosis on the incidence of preterm delivery. Most studies did not show an increased risk for congenital anomalies or other adverse fetal outcomes following metronidazole exposure during pregnancy. Three studies conducted to assess the risk of infant cancer following metronidazole exposure during pregnancy did not show an increased risk; however, the ability of these studies to detect such a signal was limited. Metronidazole crosses the placental barrier and its effects on the human fetal organogenesis are not known. Reproduction studies have been performed in rats, rabbits, and mice at doses similar to the maximum recommended human dose based on body surface area comparisons. There was no evidence of harm to the fetus due to metronidazole. Nursing Mothers Metronidazole is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels. There are no data on the effects of metronidazole on milk production. Animal studies have shown the potential for tumorigenicity after oral metronidazole was administered chronically to rats and mice (see PRECAUTIONS , Carcinogenesis, Mutagenesis, Impairment of Fertility). This drug is not intended to be administered chronically; therefore, the clinical relevance of the findings of the animal studies is unclear. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for metronidazole tablets and any potential adverse effects on the breastfed infant from metronidazole tablets or from the underlying maternal condition. Alternatively, a nursing mother may choose to pump and discard human milk for the duration of metronidazole tablets therapy, and for 48 hours after the last dose and feed her infant stored human milk or formula. Geriatric Use In elderly geriatric patients, monitoring for metronidazole associated adverse events is recommended (see CLINICAL PHARMACOLOGY , PRECAUTIONS ). Decreased liver function in geriatric patients can result in increased concentrations of metronidazole that may necessitate adjustment of metronidazole dosage (see DOSAGE AND ADMINISTRATION ). Pediatric Use Safety and effectiveness in pediatric patients have not been established, except for the treatment of amebiasis. Image"],"how_supplied":["HOW SUPPLIED Product: 50090-0201 NDC: 50090-0201-0 21 TABLET, FILM COATED in a BOTTLE NDC: 50090-0201-1 28 TABLET, FILM COATED in a BOTTLE NDC: 50090-0201-2 30 TABLET, FILM COATED in a BOTTLE"],"microbiology":["Microbiology Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intracellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical. Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug's intracellular transport. The reduced form of metronidazole and free radicals can interact with DNA leading to inhibition of DNA synthesis and DNA degradation leading to death of the bacteria. The precise mechanism of action of metronidazole is unclear. Resistance A potential for development of resistance exists against metronidazole. Resistance may be due to multiple mechanisms that include decreased uptake of the drug, altered reduction efficiency, overexpression of the efflux pumps, inactivation of the drug, and/or increased DNA damage repair. Metronidazole does not possess any clinically relevant activity against facultative anaerobes or obligate aerobes. Antimicrobial Activity Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Gram-positive anaerobes Clostridium species Eubacterium species Peptococcus species Peptostreptococcus species Gram-negative anaerobes Bacteroides fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B.vulgatus ) Fusobacterium species Protozoal parasites Entamoeba histolytica Trichomonas vaginalis The following in vitro data are available, but their clinical significance is unknown: Metronidazole exhibits in vitro minimal inhibitory concentrations (MIC's) of 8 mcg/mL or less against most (≥ 90%) isolates of the following bacteria; however, the safety and effectiveness of metronidazole in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials. Gram-negative anaerobes Bacteroides fragilis group ( B. caccae, B. uniformis ) Prevotella species ( P. bivia, P. buccae, P. disiens ) Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"boxed_warning":["WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS ). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below."],"geriatric_use":["Geriatric Use In elderly geriatric patients, monitoring for metronidazole associated adverse events is recommended (see CLINICAL PHARMACOLOGY , PRECAUTIONS ). Decreased liver function in geriatric patients can result in increased concentrations of metronidazole that may necessitate adjustment of metronidazole dosage (see DOSAGE AND ADMINISTRATION )."],"pediatric_use":["Pediatric Use Safety and effectiveness in pediatric patients have not been established, except for the treatment of amebiasis."],"effective_time":"20260318","nursing_mothers":["Nursing Mothers Metronidazole is present in human milk at concentrations similar to maternal serum levels, and infant serum levels can be close to or comparable to infant therapeutic levels. There are no data on the effects of metronidazole on milk production. Animal studies have shown the potential for tumorigenicity after oral metronidazole was administered chronically to rats and mice (see PRECAUTIONS , Carcinogenesis, Mutagenesis, Impairment of Fertility). This drug is not intended to be administered chronically; therefore, the clinical relevance of the findings of the animal studies is unclear. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for metronidazole tablets and any potential adverse effects on the breastfed infant from metronidazole tablets or from the underlying maternal condition. Alternatively, a nursing mother may choose to pump and discard human milk for the duration of metronidazole tablets therapy, and for 48 hours after the last dose and feed her infant stored human milk or formula."],"adverse_reactions":["ADVERSE REACTIONS The following reactions have been reported during treatment with metronidazole: Central Nervous System: The most serious adverse reactions reported in patients treated with metronidazole have been convulsive seizures, encephalopathy, aseptic meningitis, optic and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity. Since persistent peripheral neuropathy has been reported in some patients receiving prolonged administration of metronidazole, patients should be specifically warned about these reactions and should be told to stop the drug and report immediately to their physicians if any neurologic symptoms occur. In addition, patients have reported headache, syncope, dizziness, vertigo, incoordination, ataxia, tinnitus, hearing impairment, hearing loss, confusion, dysarthria, irritability, depression, weakness, and insomnia (see WARNINGS ). Gastrointestinal: The most common adverse reactions reported have been referable to the gastrointestinal tract, particularly nausea, sometimes accompanied by headache, anorexia, and occasionally vomiting; diarrhea; epigastric distress; and abdominal cramping and constipation. Mouth : A sharp, unpleasant metallic taste is not unusual. Furry tongue, glossitis, and stomatitis have occurred; these may be associated with a sudden overgrowth of Candida which may occur during therapy. Dermatologic : Dermatitis bullous, fixed drug eruption, erythematous rash and pruritus. Hematopoietic : Reversible neutropenia (leukopenia); rarely, reversible thrombocytopenia. Cardiovascular : QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. Flattening of the T-wave may be seen in electrocardiographic tracings. Hypersensitivity: Toxic epidermal necrolysis (TEN), Stevens-Johnson Syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalized exanthematous pustulosis (AGEP) (see WARNINGS ), urticaria, erythematous rash, flushing, nasal congestion, dryness of the mouth (or vagina or vulva), and fever. Renal : Dysuria, cystitis, polyuria, incontinence, and a sense of pelvic pressure. Instances of darkened urine have been reported by approximately one patient in 100,000. Although the pigment which is probably responsible for this phenomenon has not been positively identified, it is almost certainly a metabolite of metronidazole and seems to have no clinical significance. Hepatic: Cases of severe irreversible hepatotoxicity/ acute liver failure, including cases with fatal outcomes with very rapid onset after initiation of systemic use of metronidazole, have been reported in patients with Cockayne syndrome (latency from drug start to signs of liver failure as short as 2 days) (see CONTRAINDICATIONS ). Other : Proliferation of Candida in the vagina, dyspareunia, decrease of libido, proctitis, and fleeting joint pains sometimes resembling \"serum sickness.\" Rare cases of pancreatitis, which generally abated on withdrawal of the drug, have been reported. Patients with Crohn's disease are known to have an increased incidence of gastrointestinal and certain extraintestinal cancers. There have been some reports in the medical literature of breast and colon cancer in Crohn's disease patients who have been treated with metronidazole at high doses for extended periods of time. A cause and effect relationship has not been established. Crohn's disease is not an approved indication for metronidazole tablets."],"contraindications":["CONTRAINDICATIONS Hypersensitivity Metronidazole tablet are contraindicated in patients with a prior history of hypersensitivity to metronidazole or other nitroimidazole derivatives. In patients with trichomoniasis, metronidazole tablet are contraindicated during the first trimester of pregnancy (see PRECAUTIONS ). Psychotic Reaction with Disulfiram Use of oral metronidazole is associated with psychotic reactions in alcoholic patients who were using disulfiram concurrently. Do not administer metronidazole to patients who have taken disulfiram within the last two weeks (see PRECAUTIONS, Drug Interactions ). Interaction with Alcohol Use of oral metronidazole is associated with a disulfiram-like reaction to alcohol, including abdominal cramps, nausea, vomiting, headaches, and flushing. Discontinue consumption of alcohol or products containing propylene glycol during and for at least three days after therapy with metronidazole (see PRECAUTIONS, Drug Interactions ). Cockayne Syndrome Metronidazole Tablets are contraindicated in patients with Cockayne syndrome. Severe irreversible hepatotoxicity/acute liver failure with fatal outcomes have been reported after initiation of metronidazole in patients with Cockayne syndrome (see ADVERSE REACTIONS )."],"drug_interactions":["Drug Interactions Disulfiram Psychotic reactions have been reported in alcoholic patients who are using metronidazole and disulfiram concurrently. Metronidazole should not be given to patients who have taken disulfiram within the last two weeks (see CONTRAINDICATIONS ). Alcoholic Beverages Abdominal cramps, nausea, vomiting, headaches, and flushing may occur if alcoholic beverages or products containing propylene glycol are consumed during or following metronidazole therapy (see CONTRAINDICATIONS ). Warfarin and other Oral Anticoagulants Metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other oral coumarin anticoagulants, resulting in a prolongation of prothrombin time. When metronidazole is prescribed for patients on this type of anticoagulant therapy, prothrombin time and INR should be carefully monitored. Lithium In patients stabilized on relatively high doses of lithium, short-term metronidazole therapy has been associated with elevation of serum lithium and, in a few cases, signs of lithium toxicity. Serum lithium and serum creatinine levels should be obtained several days after beginning metronidazole to detect any increase that may precede clinical symptoms of lithium intoxication. Busulfan Metronidazole has been reported to increase plasma concentrations of busulfan, which can result in an increased risk for serious busulfan toxicity. Metronidazole should not be administered concomitantly with busulfan unless the benefit outweighs the risk. If no therapeutic alternatives to metronidazole are available, and concomitant administration with busulfan is medically needed, frequent monitoring of busulfan plasma concentration should be performed and the busulfan dose should be adjusted accordingly. Drugs that Inhibit CYP450 Enzymes The simultaneous administration of drugs that decrease microsomal liver enzyme activity, such as cimetidine, may prolong the half-life and decrease plasma clearance of metronidazole. Drugs that Induce CYP450 Enzymes The simultaneous administration of drugs that induce microsomal liver enzymes, such as phenytoin or phenobarbital, may accelerate the elimination of metronidazole, resulting in reduced plasma levels; impaired clearance of phenytoin has also been reported. Drugs that Prolong the QT interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. Drug/Laboratory Test Interactions Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide adenine dinucleotide (NAD+ NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7 ."],"clinical_pharmacology":["CLINICAL PHARMACOLOGY Absorption Disposition of metronidazole in the body is similar for both oral and intravenous dosage forms. Following oral administration, metronidazole is well absorbed, with peak plasma concentrations occurring between one and two hours after administration. Plasma concentrations of metronidazole are proportional to the administered dose. Oral administration of 250 mg, 500 mg, or 2,000 mg produced peak plasma concentrations of 6 mcg/mL, 12 mcg/mL, and 40 mcg/mL, respectively. Studies reveal no significant bioavailability differences between males and females; however, because of weight differences, the resulting plasma levels in males are generally lower. Distribution Metronidazole is the major component appearing in the plasma, with lesser quantities of metabolites also being present. Less than 20% of the circulating metronidazole is bound to plasma proteins. Metronidazole appears in cerebrospinal fluid, saliva, and breast milk in concentrations similar to those found in plasma. Bactericidal concentrations of metronidazole have also been detected in pus from hepatic abscesses. Metabolism/Excretion The major route of elimination of metronidazole and its metabolites is via the urine (60% to 80% of the dose), with fecal excretion accounting for 6% to 15% of the dose. The metabolites that appear in the urine result primarily from side-chain oxidation [1-(ßhydroxyethyl)-2-hydroxymethyl-5-nitroimidazole and 2-methyl-5-nitroimidazole-1-ylacetic acid] and glucuronide conjugation, with unchanged metronidazole accounting for approximately 20% of the total. Both the parent compound and the hydroxyl metabolite possess in vitro antimicrobial activity. Renal clearance of metronidazole is approximately 10 mL/min/1.73 m 2 . The average elimination half-life of metronidazole in healthy subjects is eight hours. Renal Impairment Decreased renal function does not alter the single-dose pharmacokinetics of metronidazole. Subjects with end-stage renal disease (ESRD; CLCR= 8.1±9.1 mL/min) and who received a single intravenous infusion of metronidazole 500 mg had no significant change in metronidazole pharmacokinetics but had 2-fold higher Cmax of hydroxy-metronidazole and 5-fold higher Cmax of metronidazole acetate, compared to healthy subjects with normal renal function (CLCR= 126±16 mL/min). Thus, on account of the potential accumulation of metronidazole metabolites in ESRD patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS ). Effect of Dialysis Following a single intravenous infusion or oral dose of metronidazole 500 mg, the clearance of metronidazole was investigated in ESRD subjects undergoing hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). A hemodialysis session lasting for 4 to 8 hours removed 40% to 65% of the administered metronidazole dose, depending on the type of dialyzer membrane used and the duration of the dialysis session. If the administration of metronidazole cannot be separated from the dialysis session, supplementation of metronidazole dose following hemodialysis should be considered (see DOSAGE AND ADMINISTRATION ). A peritoneal dialysis session lasting for 7.5 hours removed approximately 10% of the administered metronidazole dose. No adjustment in metronidazole dose is needed in ESRD patients undergoing CAPD. Hepatic Impairment Following a single intravenous infusion of 500 mg metronidazole, the mean AUC24 of metronidazole was higher by 114% in patients with severe (Child-Pugh C) hepatic impairment, and by 54% and 53% in patients with mild (Child-Pugh A) and moderate (Child-Pugh B) hepatic impairment, respectively, compared to healthy control subjects. There were no significant changes in the AUC24 of hydroxyl-metronidazole in these hepatically impaired patients. A reduction in metronidazole dosage by 50% is recommended in patients with severe (Child-Pugh C) hepatic impairment (see DOSAGE AND ADMINISTRATION ). No dosage adjustment is needed for patients with mild to moderate hepatic impairment. Patients with mild to moderate hepatic impairment should be monitored for metronidazole associated adverse events (see PRECAUTIONS and DOSAGE AND ADMINISTRATION ). Geriatric Patients Following a single 500 mg oral or IV dose of metronidazole, subjects >70 years old with no apparent renal or hepatic dysfunction had a 40% to 80% higher mean AUC of hydroxy-metronidazole (active metabolite), with no apparent increase in the mean AUC of metronidazole (parent compound), compared to young healthy controls <40 years old. In geriatric patients, monitoring for metronidazole associated adverse events is recommended (see PRECAUTIONS ). Pediatric Patients In one study, newborn infants appeared to demonstrate diminished capacity to eliminate metronidazole. The elimination half-life, measured during the first 3 days of life, was inversely related to gestational age. In infants whose gestational ages were between 28 and 40 weeks, the corresponding elimination half-lives ranged from 109 to 22.5 hours. Microbiology Mechanism of Action Metronidazole, a nitroimidazole, exerts antibacterial effects in an anaerobic environment against most obligate anaerobes. Once metronidazole enters the organism by passive diffusion and activated in the cytoplasm of susceptible anaerobic bacteria, it is reduced; this process includes intracellular electron transport proteins such as ferredoxin, transfer of an electron to the nitro group of the metronidazole, and formation of a short-lived nitroso free radical. Because of this alteration of the metronidazole molecule, a concentration gradient is created and maintained which promotes the drug's intracellular transport. The reduced form of metronidazole and free radicals can interact with DNA leading to inhibition of DNA synthesis and DNA degradation leading to death of the bacteria. The precise mechanism of action of metronidazole is unclear. Resistance A potential for development of resistance exists against metronidazole. Resistance may be due to multiple mechanisms that include decreased uptake of the drug, altered reduction efficiency, overexpression of the efflux pumps, inactivation of the drug, and/or increased DNA damage repair. Metronidazole does not possess any clinically relevant activity against facultative anaerobes or obligate aerobes. Antimicrobial Activity Metronidazole has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Gram-positive anaerobes Clostridium species Eubacterium species Peptococcus species Peptostreptococcus species Gram-negative anaerobes Bacteroides fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B.vulgatus ) Fusobacterium species Protozoal parasites Entamoeba histolytica Trichomonas vaginalis The following in vitro data are available, but their clinical significance is unknown: Metronidazole exhibits in vitro minimal inhibitory concentrations (MIC's) of 8 mcg/mL or less against most (≥ 90%) isolates of the following bacteria; however, the safety and effectiveness of metronidazole in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials. Gram-negative anaerobes Bacteroides fragilis group ( B. caccae, B. uniformis ) Prevotella species ( P. bivia, P. buccae, P. disiens ) Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC."],"indications_and_usage":["INDICATIONS AND USAGE Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, Metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy."],"information_for_patients":["Information for Patients Interaction with Alcohol Discontinue consumption of alcoholic beverages or products containing propylene glycol while taking metronidazole and for at least three days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur (see CONTRAINDICATIONS and PRECAUTIONS, Drug Interactions ). Treatment of Bacterial and Parasitic Infections Patients should be counseled that metronidazole should only be used to treat bacterial and parasitic infections. Metronidazole does not treat viral infections ( e.g., the common cold). When metronidazole is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by metronidazole in the future. Severe Cutaneous Adverse Reactions Advise patients that metronidazole tablets may increase the risk of serious and sometimes fatal dermatologic reactions, including toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), and drug reaction with eosinophilia and systemic symptoms (DRESS). Instruct the patient to be alert for skin rash, blisters, fever or other signs and symptoms of these hypersensitivity reactions. Advise patients to stop metronidazole tablets immediately if they develop any type of rash and seek medical attention."],"spl_unclassified_section":["To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria."],"dosage_and_administration":["DOSAGE AND ADMINISTRATION Trichomoniasis: In the Female: One-day treatment − two grams of metronidazole tablets, given either as a single dose or in two divided doses of one gram each, given in the same day. Seven-day course of treatment − 250 mg three times daily for seven consecutive days. There is some indication from controlled comparative studies that cure rates as determined by vaginal smears and signs and symptoms, may be higher after a seven-day course of treatment than after a one-day treatment regimen. The dosage regimen should be individualized. Single-dose treatment can assure compliance, especially if administered under supervision, in those patients who cannot be relied on to continue the seven-day regimen. A seven-day course of treatment may minimize reinfection by protecting the patient long enough for the sexual contacts to obtain appropriate treatment. Further, some patients may tolerate one treatment regimen better than the other. Pregnant patients should not be treated during the first trimester (see CONTRAINDICATIONS ). In pregnant patients for whom alternative treatment has been inadequate, the one-day course of therapy should not be used, as it results in higher serum levels which can reach the fetal circulation (see PRECAUTIONS, Pregnancy ). When repeat courses of the drug are required, it is recommended that an interval of four to six weeks elapse between courses and that the presence of the trichomonad be reconfirmed by appropriate laboratory measures. Total and differential leukocyte counts should be made before and after re-treatment. In the Male: Treatment should be individualized as it is for the female. Amebiasis Adults: For acute intestinal amebiasis (acute amebic dysentery): 750 mg orally three times daily for 5 to 10 days. For amebic liver abscess: 500 mg or 750 mg orally three times daily for 5 to 10 days. Pediatric patients : 35 to 50 mg/kg/24 hours, divided into three doses, orally for 10 days. Anaerobic Bacterial Infections In the treatment of most serious anaerobic infections, intravenous metronidazole is usually administered initially. The usual adult oral dosage is 7.5 mg/kg every six hours (approx. 500 mg for a 70-kg adult). A maximum of 4 g should not be exceeded during a 24-hour period. The usual duration of therapy is 7 to 10 days; however, infections of the bone and joint, lower respiratory tract, and endocardium may require longer treatment. Dosage Adjustments Patients with Severe Hepatic Impairment For patients with severe hepatic impairment (Child-Pugh C), the dose of metronidazole tablets should be reduced by 50% (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). Patients Undergoing Hemodialysis: Hemodialysis removes significant amounts of metronidazole and its metabolites from systemic circulation. The clearance of metronidazole will depend on the type of dialysis membrane used, the duration of the dialysis session, and other factors. If the administration of metronidazole cannot be separated from the hemodialysis session, supplementation of metronidazole dosage following the hemodialysis session should be considered, depending on the patient's clinical situation (see CLINICAL PHARMACOLOGY )."],"spl_product_data_elements":["Metronidazole Metronidazole METRONIDAZOLE METRONIDAZOLE HYDROXYPROPYL CELLULOSE (90000 WAMW) HYDROXYPROPYL CELLULOSE, LOW SUBSTITUTED HYPROMELLOSE 2910 (5 MPA.S) PEG-8 POWDERED CELLULOSE STEARIC ACID TITANIUM DIOXIDE U;226"],"package_label_principal_display_panel":["Metronidazole Label Image"]},"tags":[{"label":"Nitroimidazole Antimicrobial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"A01AB17","category":"atc"},{"label":"Oral","category":"route"},{"label":"Topical","category":"route"},{"label":"Capsule","category":"form"},{"label":"Cream","category":"form"},{"label":"Gel","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Abdominal abscess","category":"indication"},{"label":"Abscess of brain","category":"indication"},{"label":"Abscess of liver","category":"indication"},{"label":"Acute amebiasis","category":"indication"},{"label":"Amebic dysentery","category":"indication"},{"label":"Amebic liver abscess","category":"indication"},{"label":"Baxter Hlthcare","category":"company"},{"label":"Approved 1960s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiprotozoal Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":["WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS ). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below."],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"5500 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"4813 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"4215 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"4116 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"3360 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"3268 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"3160 reports"},{"date":"","signal":"DRUG HYPERSENSITIVITY","source":"FDA FAERS","actionTaken":"3146 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"3019 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"2991 reports"}],"drugInteractions":[{"url":"/drug/phenobarbital","drug":"phenobarbital","action":"Monitor closely","effect":"May interact with Phenobarbital","source":"DrugCentral","drugSlug":"phenobarbital"},{"url":"/drug/phenprocoumon","drug":"phenprocoumon","action":"Monitor closely","effect":"May interact with Phenprocoumon","source":"DrugCentral","drugSlug":"phenprocoumon"},{"url":"/drug/warfarin","drug":"warfarin","action":"Avoid combination","effect":"May interact with Warfarin","source":"DrugCentral","drugSlug":"warfarin"}],"commonSideEffects":[{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Diarrhea","drugRate":"reported","severity":"unknown"},{"effect":"Abdominal cramping","drugRate":"reported","severity":"unknown"},{"effect":"Constipation","drugRate":"reported","severity":"unknown"},{"effect":"Vomiting","drugRate":"reported","severity":"unknown"},{"effect":"Anorexia","drugRate":"reported","severity":"unknown"},{"effect":"Headache","drugRate":"reported","severity":"unknown"},{"effect":"Epigastric distress","drugRate":"reported","severity":"unknown"},{"effect":"Dysuria","drugRate":"reported","severity":"unknown"},{"effect":"Cystitis","drugRate":"reported","severity":"unknown"},{"effect":"Polyuria","drugRate":"reported","severity":"unknown"},{"effect":"Incontinence","drugRate":"reported","severity":"unknown"},{"effect":"Sense of pelvic pressure","drugRate":"reported","severity":"unknown"},{"effect":"Darkened urine","drugRate":"1 in 100,000","severity":"unknown","_validated":true},{"effect":"Proliferation of Candida in the vagina","drugRate":"reported","severity":"unknown"},{"effect":"Dyspareunia","drugRate":"reported","severity":"unknown"},{"effect":"Decrease of libido","drugRate":"reported","severity":"unknown"},{"effect":"Proctitis","drugRate":"reported","severity":"unknown"},{"effect":"Fleeting joint pains","drugRate":"reported","severity":"unknown"},{"effect":"Pancreatitis","drugRate":"reported","severity":"unknown"},{"effect":"Erythematous rash","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Stevens-Johnson Syndrome","drugRate":"reported","severity":"unknown"},{"effect":"Toxic epidermal necrolysis","drugRate":"reported","severity":"unknown"},{"effect":"Flushing","drugRate":"reported","severity":"unknown"},{"effect":"Nasal congestion","drugRate":"reported","severity":"unknown"},{"effect":"Dryness of the mouth","drugRate":"reported","severity":"unknown"},{"effect":"Fever","drugRate":"reported","severity":"unknown"},{"effect":"Reversible neutropenia","drugRate":"reported","severity":"unknown"}],"contraindications":["Alcohol intoxication","Alcoholism","Blood coagulation disorder","Breastfeeding (mother)","Diabetes mellitus","Disease of blood AND/OR blood-forming organ","Disease of liver","Disorder of brain","Disorder of optic nerve","Edema","Epilepsy","Gout","Hepatic failure","Kidney disease","Leukopenia","Lowered convulsive threshold","Neutropenic disorder","Non-infective meningitis","Peripheral nerve disease","Pregnancy, function","Seizure disorder","Skin irritation"],"specialPopulations":{"Pregnancy":"Pregnancy Category B. There are no adequate and well-controlled studies with the use of metronidazole topical cream in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.","Geriatric use":"In geriatric patients, monitoring for metronidazole associated adverse events is recommended. Decreased liver function in geriatric patients can result in increased concentrations of metronidazole that may necessitate adjustment of metronidazole dosage.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established."}},"trials":[],"aliases":[],"company":"Baxter","patents":[{"type":"Method of Use","number":"9198858","applicant":"CHEMO RESEARCH SL","territory":"US","tradeName":"NUVESSA","expiryDate":"2032-06-28"},{"type":"Method of Use","number":"8658678","applicant":"CHEMO RESEARCH SL","territory":"US","tradeName":"NUVESSA","expiryDate":"2028-06-27"},{"type":"Formulation","number":"12257236","applicant":"SAPTALIS PHARMACEUTICALS LLC","territory":"US","tradeName":"LIKMEZ","expiryDate":"2039-01-16"},{"type":"Method of Use","number":"8946276","applicant":"CHEMO RESEARCH SL","territory":"US","tradeName":"NUVESSA","expiryDate":"2032-06-28"},{"type":"Formulation","number":"11541035","applicant":"SAPTALIS PHARMACEUTICALS LLC","territory":"US","tradeName":"LIKMEZ","expiryDate":"2039-10-04"},{"type":"Formulation","number":"7893097","applicant":"CHEMO RESEARCH SL","territory":"US","tradeName":"NUVESSA","expiryDate":"2028-02-19"},{"type":"Formulation","number":"8877792","applicant":"CHEMO RESEARCH SL","territory":"US","tradeName":"NUVESSA","expiryDate":"2028-02-02"},{"type":"Formulation","number":"10238634","applicant":"CHEMO RESEARCH SL","territory":"US","tradeName":"NUVESSA","expiryDate":"2032-06-28"},{"type":"Formulation","number":"10596155","applicant":"CHEMO RESEARCH SL","territory":"US","tradeName":"NUVESSA","expiryDate":"2032-06-28"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.4806/GM","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$175","description":"METRONIDAZOLE 0.75% CREAM","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=METRONIDAZOLE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:49:16.752421+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:49:16.752282+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:49:23.124497+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:49:15.375139+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METRONIDAZOLE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:49:23.945533+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:13.903839+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:13.903906+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING Metronidazole has been shown to be carcinogenic in mice and rats (see PRECAUTIONS ). Unnecessary use of the drug should be avoided. Its use should be reserved for the conditions described in the INDICATIONS AND USAGE section below.","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:13.903925+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:49:25.557819+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:24.506150+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL137/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:24.416666+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA203458","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:13.903937+00:00"}},"allNames":"metro i.v. in plastic container","offLabel":[],"synonyms":["metronidazole","anagiardil","metronidazol","metropol","metrotab","mexibol","nidazole","trichazol","trichobrol","metronidazole hydrochloride","metronidazole phosphate","metronidazole benzoate","metronidazole HCl","rozex"],"timeline":[{"date":"1963-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from GD SEARLE LLC to Baxter Hlthcare"},{"date":"1963-07-18","type":"positive","source":"DrugCentral","milestone":"FDA approval (Gd Searle Llc)"},{"date":"1982-08-31","type":"positive","source":"FDA Orange Book","milestone":"Metro I.V. approved — 500MG/100ML"},{"date":"1982-10-22","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Fosun Pharma)"},{"date":"1982-12-20","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Watson Labs)"},{"date":"1983-02-16","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Mutual Pharm)"},{"date":"1983-03-02","type":"positive","source":"FDA Orange Book","milestone":"Protostat approved — 250MG"},{"date":"1983-06-02","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Fosun Pharma)"},{"date":"1983-08-18","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Chartwell Molecules)"},{"date":"1983-09-29","type":"positive","source":"FDA Orange Book","milestone":"Metro I.V. In Plastic Container approved — 500MG/100ML"},{"date":"1983-11-18","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Abbott)"},{"date":"1984-02-13","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Watson Labs)"},{"date":"1984-03-30","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Hikma)"},{"date":"1984-04-10","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Lnk)"},{"date":"1986-04-01","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 10 manufacturers approved"},{"date":"1988-11-22","type":"positive","source":"FDA Orange Book","milestone":"Metrogel approved — 0.75% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"1992-08-17","type":"positive","source":"FDA Orange Book","milestone":"Metrogel-Vaginal approved — 0.75%"},{"date":"1995-05-03","type":"positive","source":"FDA Orange Book","milestone":"Flagyl approved — 375MG"},{"date":"1995-09-20","type":"positive","source":"FDA Orange Book","milestone":"Metrocream approved — 0.75%"},{"date":"1997-09-26","type":"positive","source":"FDA Orange Book","milestone":"Noritate approved — 1%"},{"date":"1997-11-26","type":"positive","source":"FDA Orange Book","milestone":"Flagyl Er approved — 750MG"},{"date":"1998-11-24","type":"positive","source":"FDA Orange Book","milestone":"Metrolotion approved — 0.75%"},{"date":"2005-05-20","type":"positive","source":"FDA Orange Book","milestone":"Vandazole approved — 0.75%"},{"date":"2005-06-30","type":"positive","source":"FDA Orange Book","milestone":"Metrogel approved — 1%"},{"date":"2014-03-24","type":"positive","source":"FDA Orange Book","milestone":"Nuvessa approved — 1.3%"},{"date":"2014-07-04","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Pfizer Japan Inc.)"},{"date":"2023-09-22","type":"positive","source":"FDA Orange Book","milestone":"Likmez approved — 500MG/5ML"}],"aiSummary":"Metro I.V. In Plastic Container (Metronidazole) is a nitroimidazole antimicrobial drug developed by GD Searle LLC and currently owned by Baxter Healthcare. It is a small molecule modality that has been FDA-approved since 1963 for various bacterial and protozoal infections, including abdominal abscesses, amebiasis, and bacterial endocarditis. The drug is highly bioavailable (99%) and has a half-life of 7.1 hours. Metro I.V. is available as a generic medication, with 38 manufacturers listed in the Orange Book. As an off-patent medication, it is widely available and used to treat a range of infections.","approvals":[{"date":"1963-07-18","orphan":false,"company":"GD SEARLE LLC","regulator":"FDA"},{"date":"2014-07-04","orphan":false,"company":"Pfizer Japan Inc.","regulator":"PMDA"}],"brandName":"Metro I.V. In Plastic Container","ecosystem":[{"indication":"Abdominal abscess","otherDrugs":[{"name":"cefoxitin","slug":"cefoxitin","company":""},{"name":"ceftolozane","slug":"ceftolozane","company":"Cubist Pharms"},{"name":"cilastatin","slug":"cilastatin","company":"Merck"},{"name":"ciprofloxacin","slug":"ciprofloxacin","company":"Bayer Hlthcare"}],"globalPrevalence":89000},{"indication":"Abscess of brain","otherDrugs":[],"globalPrevalence":null},{"indication":"Abscess of liver","otherDrugs":[{"name":"ceftolozane","slug":"ceftolozane","company":"Cubist Pharms"},{"name":"tazobactam","slug":"tazobactam","company":""}],"globalPrevalence":null},{"indication":"Acute amebiasis","otherDrugs":[{"name":"paromomycin","slug":"paromomycin","company":""},{"name":"tinidazole","slug":"tinidazole","company":"Mission Pharma"}],"globalPrevalence":null},{"indication":"Amebic dysentery","otherDrugs":[],"globalPrevalence":null},{"indication":"Amebic liver abscess","otherDrugs":[{"name":"tinidazole","slug":"tinidazole","company":"Mission Pharma"}],"globalPrevalence":null},{"indication":"B. Fragilis Infections","otherDrugs":[],"globalPrevalence":null},{"indication":"Bacterial endocarditis","otherDrugs":[{"name":"ampicillin","slug":"ampicillin","company":"Wyeth Ayerst"},{"name":"benzylpenicillin","slug":"benzylpenicillin","company":"Pfizer"},{"name":"cefapirin","slug":"cefapirin","company":"Apothecon"},{"name":"cefazolin","slug":"cefazolin","company":"Glaxosmithkline"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Nitroimidazole Antimicrobial [EPC]","explanation":"","oneSentence":"","technicalDetail":"Metronidazole exerts its antimicrobial effects by undergoing reduction to form free radicals, which damage DNA and disrupt cellular processes, ultimately leading to cell death."},"commercial":{"launchDate":"1963","_launchSource":"DrugCentral (FDA 1963-07-18, GD SEARLE LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1790","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=METRONIDAZOLE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METRONIDAZOLE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T14:31:05.438683","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:49:30.232781+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"hydrogen peroxide","drugSlug":"hydrogen-peroxide","fdaApproval":"","patentExpiry":"Jul 4, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"chlorhexidine","drugSlug":"chlorhexidine","fdaApproval":"1976-09-17","patentExpiry":"Oct 2, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"amphotericin B","drugSlug":"amphotericin-b","fdaApproval":"1964-11-12","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"oxyquinoline","drugSlug":"oxyquinoline","fdaApproval":"","relationship":"same-class"},{"drugName":"neomycin","drugSlug":"neomycin","fdaApproval":"1957-03-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"miconazole","drugSlug":"miconazole","fdaApproval":"1974-01-08","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"natamycin","drugSlug":"natamycin","fdaApproval":"1978-10-30","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tetracycline","drugSlug":"tetracycline","fdaApproval":"1953-11-19","genericCount":34,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"clotrimazole","drugSlug":"clotrimazole","fdaApproval":"1975-02-03","patentExpiry":"May 26, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"chlortetracycline","drugSlug":"chlortetracycline","fdaApproval":"1950-01-23","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"doxycycline","drugSlug":"doxycycline","fdaApproval":"1967-12-05","patentExpiry":"Dec 19, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"minocycline","drugSlug":"minocycline","fdaApproval":"1971-06-30","patentExpiry":"Sep 8, 2037","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"oxytetracycline","drugSlug":"oxytetracycline","fdaApproval":"1964-09-08","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"metronidazole","indications":{"approved":[{"name":"Abdominal abscess","source":"DrugCentral","snomedId":75100008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":89000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Infect Dis, 2019 (PMID:31285144)"},{"name":"Abscess of brain","source":"DrugCentral","snomedId":441806004,"regulator":"FDA"},{"name":"Abscess of liver","source":"DrugCentral","snomedId":27916005,"regulator":"FDA"},{"name":"Acute amebiasis","source":"DrugCentral","snomedId":39224005,"regulator":"FDA"},{"name":"Amebic dysentery","source":"DrugCentral","snomedId":387754006,"regulator":"FDA"},{"name":"Amebic liver abscess","source":"DrugCentral","snomedId":75119003,"regulator":"FDA"},{"name":"B. Fragilis Infections","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacterial endocarditis","source":"DrugCentral","snomedId":301183007,"regulator":"FDA"},{"name":"Bacterial septicemia","source":"DrugCentral","snomedId":10001005,"regulator":"FDA"},{"name":"Bacterial vaginosis","source":"DrugCentral","snomedId":419760006,"regulator":"FDA"},{"name":"Bacteroides Brain Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Empyema","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Endocarditis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Endomyometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Joint Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Liver Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Osteomyelitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Pneumonia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Bacteroides Tubo-Ovarian Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Endomyometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Liver Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Septicemia","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Clostridium Tubo-Ovarian Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Colorectal Perioperative Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Duodenal Ulcer due to H. Pylori","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Endometritis","source":"DrugCentral","snomedId":78623009,"regulator":"FDA"},{"name":"Eubacterium Liver Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Eubacterium Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Female genital tract infection","source":"DrugCentral","snomedId":125585007,"regulator":"FDA"},{"name":"Giardiasis","source":"DrugCentral","snomedId":58265007,"regulator":"FDA"},{"name":"Infection by Trichomonas","source":"DrugCentral","snomedId":56335008,"regulator":"FDA"},{"name":"Infection due to anaerobic bacteria","source":"DrugCentral","snomedId":423451008,"regulator":"FDA"},{"name":"Infection of bone","source":"DrugCentral","snomedId":111253001,"regulator":"FDA"},{"name":"Infection of skin AND/OR subcutaneous tissue","source":"DrugCentral","snomedId":19824006,"regulator":"FDA"},{"name":"Infectious disease of abdomen","source":"DrugCentral","snomedId":128070006,"regulator":"FDA"},{"name":"Infectious disorder of joint","source":"DrugCentral","snomedId":363162000,"regulator":"FDA"},{"name":"Infectious inflammation of intestine","source":"DrugCentral","snomedId":55184003,"regulator":"FDA"},{"name":"Intra-Abdominal Anaerobic Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Intra-Abdominal Bacteroides Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Intra-Abdominal Clostridium Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Intra-Abdominal Eubacterium Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Intra-Abdominal Peptococcus Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Intra-Abdominal Peptostreptococcus Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Lower respiratory tract infection","source":"DrugCentral","snomedId":50417007,"regulator":"FDA"},{"name":"Meningitis due to Bacteroides","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptococcus Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptococcus Endomyometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptococcus Liver Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptococcus Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptococcus Tubo-Ovarian Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptostreptococcus Endometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptostreptococcus Endomyometritis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptostreptococcus Liver Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptostreptococcus Peritonitis","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptostreptococcus Tubo-Ovarian Abscess","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Peptostreptococcus infection","source":"DrugCentral","snomedId":135341000119101,"regulator":"FDA"},{"name":"Peritonitis","source":"DrugCentral","snomedId":48661000,"regulator":"FDA"},{"name":"Post-Operative Vaginal Cuff Peptostreptococcus Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Prevention of Perioperative Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Rosacea","source":"DrugCentral","snomedId":398909004,"regulator":"FDA","usPrevalence":null,"globalPrevalence":434000000,"prevalenceMethod":"curated","prevalenceSource":"Br J Dermatol, 2018 (PMID:29478264)"},{"name":"Septicemia due to Bacteroides","source":"DrugCentral","snomedId":79587009,"regulator":"FDA"},{"name":"Skin and Skin Structure Bacteroides Fragilis Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Skin and Skin Structure Clostridium Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Skin and Skin Structure Fusobacterium Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Skin and Skin Structure Peptococcus Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Tubo-ovarian abscess","source":"DrugCentral","snomedId":58949002,"regulator":"FDA"},{"name":"Vaginal Cuff Surgery Post-Op Bacteroides Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Vaginal Cuff Surgery Post-Op Clostridium Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Vaginal Cuff Surgery Post-Op Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Vaginal Cuff Surgery Post-Op Peptococcus Infection","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Balantidiasis","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":32,"evidenceLevel":"moderate"},{"name":"Crohn's disease","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":595,"evidenceLevel":"strong"},{"name":"Diabetic Foot Infection","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":46,"evidenceLevel":"moderate"},{"name":"Diverticulitis of gastrointestinal tract","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":9,"evidenceLevel":"emerging"},{"name":"Gas gangrene caused by clostridium perfringens","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":7,"evidenceLevel":"emerging"},{"name":"Helicobacter pylori-associated gastritis","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":66,"evidenceLevel":"strong"},{"name":"Infection by Dracunculus medinensis","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":18,"evidenceLevel":"moderate"},{"name":"Periodontal Infections","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":691,"evidenceLevel":"strong"},{"name":"Pseudomembranous enterocolitis","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":735,"evidenceLevel":"strong"},{"name":"Pyrexia of unknown origin","source":"DrugCentral","drugName":"METRONIDAZOLE","evidenceCount":31,"evidenceLevel":"moderate"},{"name":"Recurrent Persistent Urethritis","source":"DrugCentral","drugName":"METRONIDAZOLE"},{"name":"Sexual Transmitted Disease Exposure from Sexual Assault","source":"DrugCentral","drugName":"METRONIDAZOLE"}],"pipeline":[]},"currentOwner":"Baxter Hlthcare","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"hydrogen-peroxide","brandName":"hydrogen peroxide","genericName":"hydrogen peroxide","approvalYear":"","relationship":"same-class"},{"drugId":"chlorhexidine","brandName":"chlorhexidine","genericName":"chlorhexidine","approvalYear":"1976","relationship":"same-class"},{"drugId":"amphotericin-b","brandName":"amphotericin B","genericName":"amphotericin B","approvalYear":"1964","relationship":"same-class"},{"drugId":"oxyquinoline","brandName":"oxyquinoline","genericName":"oxyquinoline","approvalYear":"","relationship":"same-class"},{"drugId":"neomycin","brandName":"neomycin","genericName":"neomycin","approvalYear":"1957","relationship":"same-class"},{"drugId":"miconazole","brandName":"miconazole","genericName":"miconazole","approvalYear":"1974","relationship":"same-class"},{"drugId":"natamycin","brandName":"natamycin","genericName":"natamycin","approvalYear":"1978","relationship":"same-class"},{"drugId":"tetracycline","brandName":"tetracycline","genericName":"tetracycline","approvalYear":"1953","relationship":"same-class"},{"drugId":"clotrimazole","brandName":"clotrimazole","genericName":"clotrimazole","approvalYear":"1975","relationship":"same-class"},{"drugId":"chlortetracycline","brandName":"chlortetracycline","genericName":"chlortetracycline","approvalYear":"1950","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07498582","phase":"NA","title":"AI Tool to Reduce Clinician Documentation Burden","status":"ENROLLING_BY_INVITATION","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-03-30","conditions":["Burnout, Healthcare Workers","Clinical Workflow Optimization","Health Information Technology","Electronic Health Records"],"enrollment":150,"completionDate":"2026-06"},{"nctId":"NCT06692335","phase":"NA","title":"HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2025-02-06","conditions":["Uterine Fibroids (UF)"],"enrollment":112,"completionDate":"2027-12-31"},{"nctId":"NCT07344155","phase":"","title":"SOAR: Surgery Objective Analysis and Review","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-04","conditions":["Surgical Education and Skill Acquisition"],"enrollment":100,"completionDate":"2027-12"},{"nctId":"NCT06582199","phase":"NA","title":"Precision Medicine in Alzheimer's Disease : Integration of Resilience Metrics and Risk Factors - Validation Cohort BioCogBank-AD","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-10-31","conditions":["Alzheimer Disease"],"enrollment":244,"completionDate":"2027-09"},{"nctId":"NCT07492602","phase":"NA","title":"Comparison of Gait Metrics in Patients With Stroke, Traumatic Brain Injury, and Multiple Sclerosis","status":"NOT_YET_RECRUITING","sponsor":"Casa Colina Hospital and Centers for Healthcare","startDate":"2026-04-01","conditions":["Stroke","Traumatic Brain Injury","Multiple Sclerosis"],"enrollment":90,"completionDate":"2027-02-01"},{"nctId":"NCT05639647","phase":"PHASE2","title":"Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-04-18","conditions":["Gram-negative Bacterial Infections"],"enrollment":48,"completionDate":"2026-08-17"},{"nctId":"NCT06996665","phase":"NA","title":"Diaphragmatic Physiology Similarity Index May Titrate HFNC Flow Setting: A Prospective Observational Study","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2025-06-01","conditions":["Respiratory Failure"],"enrollment":100,"completionDate":"2026-12-02"},{"nctId":"NCT06524232","phase":"NA","title":"The STop UNhealthy Substance Use Now Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ohio State University","startDate":"2024-09-16","conditions":["Risky Health Behavior","Substance Use Disorders","Substance Abuse","Alcohol Use Disorder","Drinking, Alcohol","Substance Use"],"enrollment":144,"completionDate":"2027-09"},{"nctId":"NCT07470463","phase":"","title":"Evaluation of One-Shot Vision Differential Diagnosis (OSVDE) and Multi-Step Conversational Non-Inferiority (MSCNE) in AI Medical Interviewing","status":"RECRUITING","sponsor":"Magic Health Inc. (d.b.a. Nolla Health)","startDate":"2026-03-19","conditions":["Differential Diagnosis","Diagnostic Accuracy"],"enrollment":30,"completionDate":"2026-09-19"},{"nctId":"NCT06561711","phase":"PHASE4","title":"Optimization of Minocycline for Helicobacter Pylori Rescue Treatment","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2024-08-21","conditions":["Helicobacter Pylori Infection"],"enrollment":480,"completionDate":"2026-02-21"},{"nctId":"NCT07492134","phase":"PHASE2","title":"APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)","status":"NOT_YET_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2026-04-01","conditions":["Acute Uncomplicated Diverticulitis"],"enrollment":100,"completionDate":"2028-10-01"},{"nctId":"NCT07490444","phase":"PHASE2","title":"Metric-Optimized Spectacle Prescriptions for Children With Down Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Ohio State University","startDate":"2026-04-13","conditions":["Refractive Error Correction","Visual Acuity"],"enrollment":24,"completionDate":"2028-05-01"},{"nctId":"NCT05521399","phase":"","title":"Heart Transplantation - Renewal","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2021-11-19","conditions":["Transplant, Heart","Magnetic Resonance Imaging"],"enrollment":247,"completionDate":"2030-01-31"},{"nctId":"NCT05340738","phase":"NA","title":"AI-Based Fidelity Feedback to Enhance CBT","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2023-03-09","conditions":["Cognitive Behavioral Therapy","Therapy"],"enrollment":449,"completionDate":"2026-01-31"},{"nctId":"NCT03633123","phase":"PHASE2","title":"D-PLEX 310: Safety and Efficacy of D-PLEX in the Prevention of Post Abdominal Surgery Incisional Infection","status":"COMPLETED","sponsor":"PolyPid Ltd.","startDate":"2018-10-04","conditions":["Abdominal Surgery","Colon Surgery","Post-Op Infection"],"enrollment":202,"completionDate":"2019-10-06"},{"nctId":"NCT07487142","phase":"PHASE3","title":"Prevalence of Asymptomatic H Pylori Infection Among Patients Undergoing PCI and Impact of Its Eradication on Occurrence of GIT Symptoms and Bleeding\"","status":"COMPLETED","sponsor":"Beni-Suef University","startDate":"2024-06-10","conditions":["H Pylori Infection"],"enrollment":121,"completionDate":"2025-12-24"},{"nctId":"NCT07488169","phase":"NA","title":"The Role of Physical Ardor in Triggering State Anattā and Psychophysiological Recovery","status":"COMPLETED","sponsor":"Lincoln University College","startDate":"2025-04-01","conditions":["Psychological Stress","Mental Fatigue","Self-Perception","Autonomic Nervous System Function","Post-Exercise Recovery","Healthy University Students"],"enrollment":671,"completionDate":"2026-01-15"},{"nctId":"NCT01731236","phase":"EARLY_PHASE1","title":"CARNIVAL Study: Gut Flora Dependent Metabolism of Dietary CARNItine and Phosphatidylcholine and cardioVAscuLar Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2011-02-11","conditions":["Dietary Modification"],"enrollment":100,"completionDate":"2029-12"},{"nctId":"NCT05434104","phase":"NA","title":"The LISA (Lactoferrin InStead of Antibiotics/Antifungals) Feasibility Study","status":"NOT_YET_RECRUITING","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2026-03","conditions":["Bacterial Vaginosis","Candida Vaginal"],"enrollment":114,"completionDate":"2027-12"},{"nctId":"NCT05279053","phase":"","title":"Mapping Brain Glutamate in Humans: Sex Differences in Cigarette Smokers","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2021-04-01","conditions":["Sex","Cigarette Smoking"],"enrollment":58,"completionDate":"2023-03-31"},{"nctId":"NCT06721260","phase":"","title":"Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2025-01-21","conditions":["Bladder Cancer"],"enrollment":30,"completionDate":"2027-06"},{"nctId":"NCT06462235","phase":"PHASE2","title":"A Study to Learn About the Study Medicine Aztreonam-Avibactam (ATM-AVI) in Infants and Newborns Admitted in Hospitals With Bacterial Infection (CHERISH)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-09-25","conditions":["Gram-negative Bacterial Infection"],"enrollment":48,"completionDate":"2027-12-02"},{"nctId":"NCT07481955","phase":"PHASE2","title":"Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial","status":"NOT_YET_RECRUITING","sponsor":"Freya Biosciences ApS","startDate":"2026-03-16","conditions":["Bacterial Vaginosis (BV)"],"enrollment":120,"completionDate":"2027-04-21"},{"nctId":"NCT07483671","phase":"PHASE2","title":"Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients","status":"NOT_YET_RECRUITING","sponsor":"Chengdu Syncor Pharmaceutical Co., Ltd.","startDate":"2026-04-15","conditions":["Bacterial Vaginosis"],"enrollment":80,"completionDate":"2027-01-24"},{"nctId":"NCT07239739","phase":"NA","title":"Comparing Two Medicines for Healing Jaw Bone Infections After Root Canal Treatment","status":"NOT_YET_RECRUITING","sponsor":"Faiz ur rahman","startDate":"2026-06-15","conditions":["Periapical Lesion","Periapical Periodontitis"],"enrollment":62,"completionDate":"2026-12-15"},{"nctId":"NCT04536584","phase":"NA","title":"Impact of Personalized and Remote Support Centered on Exercise and Physical Activity for Breast Cancer Patients","status":"COMPLETED","sponsor":"Centre Oscar Lambret","startDate":"2020-12-18","conditions":["Breast Cancer Female"],"enrollment":824,"completionDate":"2024-06-26"},{"nctId":"NCT07472283","phase":"","title":"Design, Development and Evaluation of a Digital Health Assistant for Paediatric Asthma","status":"NOT_YET_RECRUITING","sponsor":"University Children's Hospital Basel","startDate":"2026-04","conditions":["Paediatric Asthma"],"enrollment":42,"completionDate":"2027-05"},{"nctId":"NCT07475091","phase":"NA","title":"Standardizing Swallow Pressure Measurements","status":"NOT_YET_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-05","conditions":["Dysphagia"],"enrollment":25,"completionDate":"2027-05"},{"nctId":"NCT07426458","phase":"PHASE4","title":"Ventilation and Perfusion in Asthmatics","status":"NOT_YET_RECRUITING","sponsor":"University of Miami","startDate":"2026-04","conditions":["Asthma"],"enrollment":40,"completionDate":"2028-04"},{"nctId":"NCT07472088","phase":"","title":"Assessing the Association Between WBCT PFJ Morphological Metrics and Knee Symptoms","status":"NOT_YET_RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2026-03","conditions":["Knee Osteoarthritis","Patellofemoral Pain (PFPS)"],"enrollment":36,"completionDate":"2026-08"},{"nctId":"NCT00713947","phase":"PHASE4","title":"Effectiveness of the Eradication of Helicobacter Pylori and an Inhibitor of Pump With Proton Versus Control","status":"WITHDRAWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-04","conditions":["Positive Helicobacter Pylori Serology","Coronary Thrombosis","Supra-aortic Artery Thrombosis"],"enrollment":0,"completionDate":"2010-03"},{"nctId":"NCT05604534","phase":"","title":"Assessing and Improving Quantitative Magnetic Resonance Imaging Metrics in Human Subjects","status":"RECRUITING","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2023-02-02","conditions":["Normal Physiology"],"enrollment":200,"completionDate":"2041-03-31"},{"nctId":"NCT07463547","phase":"NA","title":"Wearable Integration in Symptom Evaluation for Cancer Survivors","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03","conditions":["Cancer"],"enrollment":20,"completionDate":"2027-02"},{"nctId":"NCT07463144","phase":"NA","title":"Evaluation of a Mobile Wellness Application and Wearable Fitness Tracker on Weight Management and Health Outcomes","status":"NOT_YET_RECRUITING","sponsor":"BetterMe Limited","startDate":"2026-03","conditions":["Obesity & Overweight"],"enrollment":300,"completionDate":"2026-08"},{"nctId":"NCT07404501","phase":"NA","title":"Gamified Approach To Burn Education","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-02","conditions":["Burn","Health Education","Accident Prevention","First Aid","Educational Intervention","Game-based Education"],"enrollment":44,"completionDate":"2026-04"},{"nctId":"NCT06903910","phase":"PHASE2","title":"Investigating the Cholinergic Contribution to Gait Dysfunction in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2024-11-01","conditions":["Parkinson Disease"],"enrollment":6,"completionDate":"2026-01-31"},{"nctId":"NCT07459387","phase":"NA","title":"REal-world Valued Outcomes of a noveL Balloon-in-basket pUlsed Field ablaTION Catheter for Atrial Fibrillation RegistrY","status":"RECRUITING","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2025-10-07","conditions":["Treatment of Atrial Fibrilation","Symptomatic Atrial Fibrillation"],"enrollment":1000,"completionDate":"2027-10-07"},{"nctId":"NCT05929794","phase":"PHASE4","title":"Pharmacokinetics of Transdermal Metronidazole","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Iowa","startDate":"2024-02-26","conditions":["Healthy"],"enrollment":24,"completionDate":"2026-12"},{"nctId":"NCT05059041","phase":"PHASE2","title":"Dilated Versus Non-Dilated Wavefront Corrections for Patients With Down Syndrome","status":"COMPLETED","sponsor":"Ohio State University","startDate":"2022-05-06","conditions":["Down Syndrome","Refractive Errors"],"enrollment":42,"completionDate":"2025-01-24"},{"nctId":"NCT07455448","phase":"","title":"Antibiotic Resistance of Helicobacter Pylori in Nanjing: A Cross-Sectional Study","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-03","conditions":["HELICOBACTER PYLORI INFECTIONS"],"enrollment":7228,"completionDate":"2026-05"},{"nctId":"NCT05813236","phase":"NA","title":"NOVOSYN® Quick Versus MONOSYN® Quick Suture Material in Resective Periodontal Surgery","status":"RECRUITING","sponsor":"Aesculap AG","startDate":"2023-06-28","conditions":["Gingivitis","Gingival Diseases","Periodontal Diseases"],"enrollment":84,"completionDate":"2026-12"},{"nctId":"NCT07451171","phase":"PHASE2","title":"Comparative Efficacy of Antibiotics for Small Intestine Bacterial Overgrowth in Bangladeshi Children","status":"NOT_YET_RECRUITING","sponsor":"University of Virginia","startDate":"2026-04","conditions":["Small Intestine Bacterial Overgrowth"],"enrollment":60,"completionDate":"2026-06"},{"nctId":"NCT06627270","phase":"PHASE2","title":"Antibiotic Treatment Effects on Intratumoral Bacteria Modulation in Surgical Patients With Oral Cancer","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-03-11","conditions":["Oral Squamous Cell Carcinoma","Oral Cancer","Head and Neck Cancer","Head and Neck Carcinoma"],"enrollment":30,"completionDate":"2027-10-01"},{"nctId":"NCT06931470","phase":"NA","title":"A Pilot Feasibility and Acceptability Study of Remote ExerciSe Training mOdalities (PRESTO)","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-04-06","conditions":["Cardiovascular Diseases"],"enrollment":30,"completionDate":"2027-12-01"},{"nctId":"NCT04983199","phase":"","title":"Patient Reported Outcomes/Metrics Program Trial","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2022-11-24","conditions":["Metastatic Cancer","Palliative"],"enrollment":100,"completionDate":"2027-09"},{"nctId":"NCT07383688","phase":"","title":"FREEDOM Registry - Follow up Revision Experience and Evaluation of Device Outcomes Metrics","status":"NOT_YET_RECRUITING","sponsor":"Neuspera Medical, Inc.","startDate":"2026-03","conditions":["Urinary Urge Incontinence"],"enrollment":100,"completionDate":"2026-10"},{"nctId":"NCT06524895","phase":"NA","title":"Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery","status":"RECRUITING","sponsor":"Albert Einstein College of Medicine","startDate":"2022-11-09","conditions":["Breast Cancer"],"enrollment":32,"completionDate":"2026-11"},{"nctId":"NCT07448103","phase":"NA","title":"Hospital and Home Rehabilitation Based on Social Care Robotics and Artificial Intelligence for Pediatric Patients","status":"NOT_YET_RECRUITING","sponsor":"Inrobics Social Robotics, S.L.","startDate":"2026-02-01","conditions":["Acquired Brain Injury"],"enrollment":30,"completionDate":"2027-02"},{"nctId":"NCT06586892","phase":"","title":"Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI as a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-09-15","conditions":["Orodental Injury"],"enrollment":300,"completionDate":"2032-12-30"},{"nctId":"NCT07445282","phase":"PHASE4","title":"This Randomized Controlled Trial Evaluates the Comparative Efficacy of Intravenous Meropenem Alone Versus Intravenous Meropenem Combined With Oral Azithromycin in Children Aged 6 Months to Under 5 Years Diagnosed With Blood Culture-confirmed Extensively Drug-resistant Uncomplicated Typhoid Fever","status":"COMPLETED","sponsor":"Sheikh Zayed Medical College","startDate":"2025-05-14","conditions":["Extensively Drug-Resistant Typhoid Fever","Typhoid Fever","Salmonella Typhi Infection"],"enrollment":90,"completionDate":"2025-11-14"},{"nctId":"NCT07446023","phase":"NA","title":"IVUS-FFR Accuracy for Coronary Stenosis","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-07-01","conditions":["Percutaneous Coronary Intervention","Intravenous Ultrasound","Coronary Physiology"],"enrollment":292,"completionDate":"2026-12-31"},{"nctId":"NCT07432919","phase":"","title":"Evaluation of the Diagnostic Capacity of a Smart Mattress Versus Conventional Polysomnography","status":"NOT_YET_RECRUITING","sponsor":"Hospital San Pedro de Logroño","startDate":"2026-11-17","conditions":["Obstructive Sleep Apnea (OSA)"],"enrollment":500,"completionDate":"2028-03-01"},{"nctId":"NCT07441850","phase":"NA","title":"Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-02-01","conditions":["Gastric Cancer"],"enrollment":186,"completionDate":"2027-03-01"},{"nctId":"NCT07438756","phase":"NA","title":"Tabata vs Burn 2 Learn Program on Body Weight, Physical Performance and Mental Well Being in School Athletes.","status":"COMPLETED","sponsor":"Riphah International University","startDate":"2023-11-23","conditions":["Sports Physical Therapy"],"enrollment":50,"completionDate":"2024-05-30"},{"nctId":"NCT07360119","phase":"NA","title":"Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors","status":"NOT_YET_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-04-01","conditions":["Periampullary Neoplasms","Pancreatic Cancer"],"enrollment":30,"completionDate":"2031-02-01"},{"nctId":"NCT06943794","phase":"NA","title":"Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":["Gastric (Stomach) Cancer"],"enrollment":4824,"completionDate":"2030-12-30"},{"nctId":"NCT06356597","phase":"PHASE2","title":"Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jing-yuan Fang, MD, Ph. D","startDate":"2024-04-19","conditions":["Colorectal Cancer"],"enrollment":33,"completionDate":"2027-12-12"},{"nctId":"NCT07429760","phase":"NA","title":"Mechanical Bowel Preparation With or Without Oral Antibiotics in Left Sided Colorectal Cancer Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"Shaukat Khanum Memorial Cancer Hospital & Research Centre","startDate":"2025-08-01","conditions":["Colorectal Cancer"],"enrollment":60,"completionDate":"2026-08-30"},{"nctId":"NCT07427589","phase":"","title":"Prospective Evaluation of New Metrics to Assess Cardiovascular Remodeling in Obstructive Sleep Apnea","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2026-03","conditions":["Obstructive Sleep Apnea","Cardiovascular (CV) Risk"],"enrollment":270,"completionDate":"2029-12"},{"nctId":"NCT04258813","phase":"NA","title":"Onco-primary Care Networking to Support TEAM-based Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Duke University","startDate":"2021-06-14","conditions":["Blood Pressure","Hypertension","Cancer","Cancer, Breast","Cancer of Prostate","Cancer Colorectal","Cancer, Endometrial","Cancer of Head and Neck","Non Small Cell Lung Cancer","CVD - Cardiovascular Disease","Diabetes Mellitus","Hypercholesterolemia","Diabetes","Cancer of Esophagus","Cancer of Liver","Cancer, Renal Cell","Cancer of Pancreas","Cancer Ovaries"],"enrollment":313,"completionDate":"2026-07-31"},{"nctId":"NCT05832177","phase":"","title":"Outreach Core Activities","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-03-22","conditions":["Cancer Education","Spanish Language Cancer Education"],"enrollment":1200,"completionDate":"2028-07"},{"nctId":"NCT03523546","phase":"NA","title":"Oncology Episode Payment Model in Hawaii","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2018-08-01","conditions":["Breast Cancer","Colon Cancer","Lung Cancer"],"enrollment":7,"completionDate":"2028-01-31"},{"nctId":"NCT07406152","phase":"NA","title":"Efficacy and Safety of ZKARE® Gel and Its Accessory ZKAPI® in the Treatment of Chronic Ulcers.","status":"RECRUITING","sponsor":"i+Med S.Coop.","startDate":"2025-11-14","conditions":["Chronic Ulcers"],"enrollment":134,"completionDate":"2026-07"},{"nctId":"NCT06616597","phase":"PHASE2","title":"Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-02-13","conditions":["Prostate Cancer (Adenocarcinoma)","Metastatic Prostate Cancer"],"enrollment":58,"completionDate":"2032-03-30"},{"nctId":"NCT06867367","phase":"NA","title":"REducing pSychological diSTress To Optimize Recovery of Elderly ICU Survivors and Caregivers (RESTORE-ICU)","status":"NOT_YET_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2026-03","conditions":["Relationship, Family","Well-Being, Psychological"],"enrollment":14,"completionDate":"2027-12"},{"nctId":"NCT05894954","phase":"PHASE3","title":"Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Alzheimer's Prevention and Reversal Project, Inc.","startDate":"2023-07-31","conditions":["Mild Cognitive Impairment","Dementia, Mild"],"enrollment":73,"completionDate":"2026-02-09"},{"nctId":"NCT07418996","phase":"PHASE2","title":"Live Double Combined Lactobacillus Capsule for Vaginal Use（IIa）","status":"COMPLETED","sponsor":"Guangdong Longchuangji Pharmaceutical Co., Ltd.","startDate":"2021-05-18","conditions":["Bacterial Vaginosis (BV)"],"enrollment":57,"completionDate":"2022-09-30"},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":["Helicobacter Pylori Infection"],"enrollment":337,"completionDate":"2024-12-03"},{"nctId":"NCT06368648","phase":"","title":"CoMind Early Feasibility Study","status":"RECRUITING","sponsor":"CoMind Technologies Limited","startDate":"2024-11-27","conditions":["Intracranial Pressure","Intracranial Pressure Changes","Traumatic Brain Injury","Intracerebral Hemorrhage","Encephalitis","Encephalopathy","Hydrocephalus","Stroke","Autoregulation"],"enrollment":581,"completionDate":"2026-11"},{"nctId":"NCT05490641","phase":"NA","title":"Know and Own Your Movement-related Metrics Via Wearable Devices","status":"COMPLETED","sponsor":"The University of Texas at Arlington","startDate":"2023-03-29","conditions":["Cancer","Survivorship"],"enrollment":60,"completionDate":"2025-12-10"},{"nctId":"NCT07411170","phase":"NA","title":"Wearable Device-Assisted Remote Management in Atrial Fibrillation Complicated by Heart Failure: WARM-HF Trial","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-03","conditions":["HFrEF - Heart Failure With Reduced Ejection Fraction","AF - Atrial Fibrillation"],"enrollment":400,"completionDate":"2028-09"},{"nctId":"NCT06401577","phase":"","title":"Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics","status":"RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2024-10-16","conditions":["Acute Pancreatitis"],"enrollment":800,"completionDate":"2027-03-31"},{"nctId":"NCT07160985","phase":"NA","title":"AI-Assisted Blood Glucose Management Study","status":"COMPLETED","sponsor":"Li Huating","startDate":"2025-09-07","conditions":["Pre-diabetes"],"enrollment":131,"completionDate":"2025-11-30"},{"nctId":"NCT07405684","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp First-line Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":["HELICOBACTER PYLORI INFECTIONS"],"enrollment":544,"completionDate":"2028-12-31"},{"nctId":"NCT07405697","phase":"PHASE4","title":"Fecal Molecular Susceptibility-guided Hp Rescue Therapy","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-02-28","conditions":["Helicobacter Pylori Infection"],"enrollment":290,"completionDate":"2028-12-31"},{"nctId":"NCT06233487","phase":"NA","title":"Reliability of Ultrasound Metrics Used in Hip Dysplasia Diagnostics - a Prospective Study","status":"COMPLETED","sponsor":"Aarhus University Hospital","startDate":"2024-02-27","conditions":["Developmental Dysplasia of the Hip"],"enrollment":74,"completionDate":"2026-02-07"},{"nctId":"NCT07312682","phase":"","title":"Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Second Affiliated Hospital of Chongqing Medical University","startDate":"2024-12-09","conditions":["Lung Neoplasms","Radiation Pneumonitis"],"enrollment":202,"completionDate":"2026-11-30"},{"nctId":"NCT07396025","phase":"NA","title":"Effectiveness of Surgical and Diagnostic Methods in Cerebral Vascular Occlusive Disease","status":"ENROLLING_BY_INVITATION","sponsor":"National Centre for Neurosurgery, Republic of Kazakhstan","startDate":"2025-07-09","conditions":["Carotid Artery Occlusion"],"enrollment":60,"completionDate":"2027-12-31"},{"nctId":"NCT06728072","phase":"PHASE2","title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-03-07","conditions":["Colorectal Cancer","CRC"],"enrollment":97,"completionDate":"2035-07-01"},{"nctId":"NCT06429332","phase":"PHASE4","title":"International Care Bundle Evaluation in Cerebral Hemorrhage Research","status":"RECRUITING","sponsor":"Region Skane","startDate":"2025-01-07","conditions":["Intracerebral Hemorrhage","Intracerebral Haemorrhage","Intraventricular Hemorrhage","Stroke","Cerebrovascular Disease"],"enrollment":3500,"completionDate":"2027-07"},{"nctId":"NCT07392047","phase":"PHASE4","title":"Metronidazole 2% Gel Versus Clindamycin 1% Gel for Moderate Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2026-02","conditions":["Acne Vulgaris"],"enrollment":60,"completionDate":"2026-08"},{"nctId":"NCT04180722","phase":"NA","title":"Transition to LIVE (Long-term In Home Ventilation Engagement) Study","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2021-03-01","conditions":["Long-term Ventilation at Home"],"enrollment":444,"completionDate":"2026-01-30"},{"nctId":"NCT04332783","phase":"NA","title":"Isolating and Mitigating Sequentially Dependent Perceptual Errors in Clinical Visual Search","status":"RECRUITING","sponsor":"University of California, Berkeley","startDate":"2019-04-01","conditions":["Vision"],"enrollment":10120,"completionDate":"2032-10-30"},{"nctId":"NCT05854212","phase":"NA","title":"Behavioral Economics to Implement Nutrition Ranking in Food Pantries","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2027-01-01","conditions":["Food Insecurity","Dietary Quality","Behavioral Economics","Implementation Science"],"enrollment":364,"completionDate":"2028-06-30"},{"nctId":"NCT07379645","phase":"NA","title":"A Clinical Trial of PepZinGI® for Acute Heartburn Relief and Sleep Outcomes","status":"NOT_YET_RECRUITING","sponsor":"NutriScience Innovations, LLC","startDate":"2026-01-15","conditions":["Heartburn"],"enrollment":50,"completionDate":"2026-07-01"},{"nctId":"NCT06434519","phase":"NA","title":"Metronidazole SC Penetrance With Moisturizers","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-03","conditions":["Rosacea, Erythematotelangiectatic"],"enrollment":21,"completionDate":"2025-11-04"},{"nctId":"NCT03663504","phase":"PHASE4","title":"Comparing No Mechanical Bowel Preparation With Oral Antibiotics Alone in Patients Undergoing Elective Colon Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2018-10-23","conditions":["Elective Colon Surgery"],"enrollment":630,"completionDate":"2026-07"},{"nctId":"NCT07265648","phase":"","title":"Assessing Diet, Stress Scores, and Other Health Metrics in Healthy Northern California Adults","status":"COMPLETED","sponsor":"USDA, Western Human Nutrition Research Center","startDate":"2025-12-08","conditions":["Chronic Stress","Stool Frequency","Food Allergies","Diet Surveys","Demographic Data"],"enrollment":300,"completionDate":"2026-01-20"},{"nctId":"NCT06551090","phase":"NA","title":"Prediction of Anxiety and Memory State","status":"RECRUITING","sponsor":"Columbia University","startDate":"2024-07-23","conditions":["Anxiety","Memory","Epilepsy"],"enrollment":40,"completionDate":"2026-12-01"},{"nctId":"NCT06396078","phase":"PHASE4","title":"Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-07-18","conditions":["Preterm Premature Rupture of Membrane","Pregnancy, High Risk","Preterm Birth"],"enrollment":56,"completionDate":"2026-12"},{"nctId":"NCT07010744","phase":"NA","title":"Effect of Triple Versus Quadruple Therapy for Treating Helicobacter Pylori Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Akil Al Islam","startDate":"2025-07-01","conditions":["Dyspepsia"],"enrollment":66,"completionDate":"2026-06"},{"nctId":"NCT07371299","phase":"","title":"Correlations Between Subjective and Objective Responses to Cochlear Implant Stimulation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-01-15","conditions":["Severe to Profound Sensorineural Hearing Loss"],"enrollment":60,"completionDate":"2029-10"},{"nctId":"NCT06612723","phase":"NA","title":"High vs Low-frequency of High-intensity Training in Chronic Stroke","status":"RECRUITING","sponsor":"Indiana University","startDate":"2024-09-16","conditions":["Stroke"],"enrollment":40,"completionDate":"2026-10"},{"nctId":"NCT07367139","phase":"NA","title":"Occupational Exposure to Whole Body Vibration Among U.S. Military Veterans: Acute and Chronic Contributions to Musculoskeletal Disorders and Spine-Area Pain","status":"NOT_YET_RECRUITING","sponsor":"Milwaukee VA Medical Center","startDate":"2026-07-01","conditions":["Spine Health","Spine Injuries and Disorders","Spine Degeneration","Whole Body Vibration"],"enrollment":112,"completionDate":"2030-06-30"},{"nctId":"NCT07368660","phase":"NA","title":"InPART RX - Epicenters","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-01-01","conditions":["Hospital Infection","Standardized Antibiotic Prescribing Ratio (SAR)"],"enrollment":169,"completionDate":"2024-12-31"},{"nctId":"NCT07357896","phase":"NA","title":"Balance Training Using Artificial Intelligence on Pelvic Asymmetry in Stroke Patients.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cairo University","startDate":"2025-12-01","conditions":["Sroke Patients"],"enrollment":38,"completionDate":"2026-03-30"},{"nctId":"NCT07358130","phase":"NA","title":"Efficacies of Bismuth-amoxicillin-vonoprazan Triple Therapy and Bismuth Quadruple Therapy","status":"RECRUITING","sponsor":"Kaohsiung Medical University","startDate":"2025-10-21","conditions":["Helicobacter Pylori Infection"],"enrollment":552,"completionDate":"2027-12-31"},{"nctId":"NCT04251481","phase":"NA","title":"Diffusion MRI for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-10-16","conditions":["Head Cancer Neck"],"enrollment":16,"completionDate":"2026-04-30"},{"nctId":"NCT07340762","phase":"","title":"Automated Reports Generation of Cardiovascular Magnetic Resonance Imaging","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-10-01","conditions":["HCM - Hypertrophic Cardiomyopathy"],"enrollment":20000,"completionDate":"2028-01-01"},{"nctId":"NCT07355101","phase":"NA","title":"Personalized Exercise Coaching to Improve Quality of Life in Pediatric IBD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universiteit Antwerpen","startDate":"2025-11-01","conditions":["Inflammatory Bowel Disease (IBD)"],"enrollment":70,"completionDate":"2027-08-01"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Cream, Gel","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride"},{"form":"CAPSULE","route":"ORAL","productName":"Metronidazole"},{"form":"CAPSULE","route":"ORAL","productName":"BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE"},{"form":"CAPSULE","route":"ORAL","productName":"Flagyl"},{"form":"CAPSULE","route":"ORAL","productName":"Pylera"},{"form":"CREAM","route":"TOPICAL","productName":"Metronidazole"},{"form":"CREAM","route":"TOPICAL","productName":"Rosadan"},{"form":"CREAM","route":"TOPICAL","productName":"MetroCream"},{"form":"CREAM","route":"TOPICAL","productName":"Metronidazole"},{"form":"CREAM","route":"TOPICAL","productName":"NORITATE"},{"form":"CREAM","route":"TOPICAL","productName":"Noritate"},{"form":"CREAM","route":"TOPICAL","productName":"METRONIDAZOLE"},{"form":"CREAM","route":"TOPICAL","productName":"Metronidazole Topical Cream"},{"form":"GEL","route":"TOPICAL","productName":"METRONIDAZOLE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146194","MMSL":"14032","NDDF":"002958","UNII":"140QMO216E","VUID":"4017836","CHEBI":"CHEBI:6909","VANDF":"4017836","INN_ID":"1032","RXNORM":"103866","UMLSCUI":"C0025872","chemblId":"CHEMBL137","ChEMBL_ID":"CHEMBL137","KEGG_DRUG":"D00409","DRUGBANK_ID":"DB00916","PDB_CHEM_ID":" 2MN","PUBCHEM_CID":"4173","SNOMEDCT_US":"1222004","IUPHAR_LIGAND_ID":"10914","SECONDARY_CAS_RN":"69198-10-3","MESH_DESCRIPTOR_UI":"D008795"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1963-","companyName":"Gd Searle Llc","relationship":"Original Developer"},{"period":"present","companyName":"Baxter Hlthcare","relationship":"Current Owner"},{"period":"2014","companyName":"Pfizer Japan Inc.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"7.1 hours","clearance":"0.85 mL/min/kg","bioavailability":"99%","fractionUnbound":"0.96%","volumeOfDistribution":"0.4 L/kg"},"publicationCount":20313,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"A01AB17","allCodes":["A01AB17","A02BD01","A02BD02","A02BD03","A02BD08","A02BD11","A02BD13","A02BD15","D06BX01","G01AF01","J01RA03","J01RA04","J01RA10","J01RA14","J01XD01","P01AB01","P01AB51","P01AB52"]},"biosimilarFilings":[],"originalDeveloper":"Gd Searle Llc","recentPublications":[{"date":"2026 Mar 27","pmid":"41905430","title":"The Unfinished Agenda in Helicobacter pylori Treatment: Resistance, Microbiome Effects, and Future Directions.","journal":"Gastroenterology"},{"date":"2026 Mar 29","pmid":"41904345","title":"UV-spectrometric study of antibiotic long-term release by different osteoplastic materials used in dentistry.","journal":"The Saudi dental journal"},{"date":"2026 Mar 27","pmid":"41903526","title":"Vaginal microbiota impacts of a Lactobacillus crispatus live biotherapeutic and predictors of colonization in randomized controlled trial.","journal":"Cell host & microbe"},{"date":"2026 Mar 28","pmid":"41902724","title":"Multifloraflavone and polyphenols from Garcinia multiflora with antioxidant, anti-acetylcholinesterase, and anti-Helicobacter pylori activities.","journal":"Natural product research"},{"date":"2026 Mar 28","pmid":"41902546","title":"The use of design of experiments and green chemistry for the preparation of a taste-masked metronidazole-loaded cubosomal nanostructured oral gel.","journal":"Pharmaceutical development and technology"}],"combinationProducts":[{"brandName":"BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE","ingredients":"bismuth subcitrate + metronidazole + tetracycline"},{"brandName":"Pylera","ingredients":"bismuth subcitrate + metronidazole + tetracycline"}],"companionDiagnostics":[],"genericManufacturers":38,"_genericFilersChecked":true,"genericManufacturerList":["Able","Abraxis Pharm","Alembic","Alembic Pharms Ltd","Amneal","Aurobindo Pharma Ltd","Baxter Hlthcare Corp","Cadila","Cadila Pharms Ltd","Chartwell Rx","Cosette","Encube","Flamingo Pharms","Fougera Pharms","Gland","Glenmark Pharms Ltd","Halsey","Inforlife","Innogenix","Intl Medication","Labs Af","Lupin Ltd","Novitium Pharma","Padagis Israel","Pliva","Rising","Savage Labs","Sciegen Pharms","Solaris Pharma Corp","Somerset Theraps Llc","Strides Pharma","Superpharm","Taro","Teva Pharms Usa","Unichem","Watson Labs","Watson Labs Inc","Zydus Lifesciences"],"status":"approved","companyName":"Baxter Hlthcare","companyId":"baxter","modality":"Small molecule","firstApprovalDate":"1963","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1963-07-18T00:00:00.000Z","mah":"GD SEARLE LLC","brand_name_local":null,"application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":"1963-07-18T00:00:00.000Z","mah":"GD SEARLE LLC","brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":"1963-07-18T00:00:00.000Z","mah":"GD SEARLE LLC","brand_name_local":null,"application_number":null},{"country_code":"SA","regulator":"SFDA","status":"likely_approved","approval_date":"1963-07-18T00:00:00.000Z","mah":"GD SEARLE LLC","brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":"1963-07-18T00:00:00.000Z","mah":"GD SEARLE LLC","brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":"1963-07-18T00:00:00.000Z","mah":"GD SEARLE LLC","brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1995-01-06T00:00:00.000Z","mah":"BAUSCH","brand_name_local":null,"application_number":"NDA020208"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-05-24T00:00:00.000Z","mah":"FOUGERA PHARMS","brand_name_local":null,"application_number":"ANDA077197"},{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2014-07-04T00:00:00.000Z","mah":"Pfizer Japan Inc.","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-10-05T00:00:00.000Z","mah":"LABS JUVISE","brand_name_local":null,"application_number":"NDA050786"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-01-27T00:00:00.000Z","mah":"GLENMARK PHARMS LTD","brand_name_local":null,"application_number":"ANDA215794"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-01-23T00:00:00.000Z","mah":"COSETTE","brand_name_local":null,"application_number":"ANDA216692"},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"patentsNormalised":[{"patent_number":"8877792","territory":"US","patent_type":"Formulation","expiry_date":"2028-02-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7893097","territory":"US","patent_type":"Formulation","expiry_date":"2028-02-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8658678","territory":"US","patent_type":"Method of Use","expiry_date":"2028-06-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9198858","territory":"US","patent_type":"Method of Use","expiry_date":"2032-06-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8946276","territory":"US","patent_type":"Method of Use","expiry_date":"2032-06-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10238634","territory":"US","patent_type":"Formulation","expiry_date":"2032-06-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10596155","territory":"US","patent_type":"Formulation","expiry_date":"2032-06-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12257236","territory":"US","patent_type":"Formulation","expiry_date":"2039-01-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11541035","territory":"US","patent_type":"Formulation","expiry_date":"2039-10-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:49:30.232781+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}